PEG10 (Paternally Expressed Gene 10) is a retrotransposon-derived, imprinted gene that plays critical roles in placental development and is aberrantly expressed in various cancers. Originally identified as a paternally expressed gene in humans, PEG10 retains sequences homologous to retrotransposon gag and pol proteins, featuring RNA-binding domains and a protease-like region. It is implicated in cellular processes such as apoptosis inhibition, cell proliferation, and viral-like particle formation, potentially influencing signaling pathways like Wnt/β-catenin.
In cancer biology, PEG10 is frequently overexpressed in hepatocellular carcinoma, prostate cancer, lung cancer, and other malignancies, where it promotes tumor growth, metastasis, and therapy resistance. Its oncogenic role has linked it to poor prognosis, making it a potential diagnostic marker or therapeutic target.
PEG10 antibodies are essential tools for detecting PEG10 protein expression and localization in tissues or cells. These antibodies, often polyclonal or monoclonal, target specific epitopes within PEG10's conserved regions. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study PEG10's functional mechanisms, tissue distribution, and association with disease progression. Validated antibodies help elucidate PEG10's role in developmental and pathological contexts, supporting research into targeted therapies or biomarkers for cancer and imprinting disorders.